Cognitive decline affects 50% six months after chemoradiotherapy for high-risk low-grade glioma

In NRG/RTOG 0424, cognitive decline affected 50% at six months and 40% at one year, despite stable average quality-of-life scores.

KEY POINTS

  • NRG/RTOG 0424 (NCT00114140) was a multicenter, single-arm phase II trial evaluating radiotherapy with concurrent and adjuvant temozolomide in patients with high-risk WHO grade II glioma. Between January 2005 and August 2009, 129 evaluable patients were enrolled, with 93 classified as participants in the neurocognitive and quality-of-life analysis. The cohort included astrocytoma, oligodendroglioma, and historically classified oligoastrocytoma, using diagnostic criteria predating contemporary molecular classification.
  • Treatment consisted of 54 Gy in 30 fractions with concurrent temozolomide 75 mg/m² daily, followed by 12 cycles of adjuvant temozolomide at 150–200 mg/m² on days 1–5 every 28 days. Neurocognitive function was assessed before treatment and at six and 12 months using the Hopkins Verbal Learning Test (HVLT), Trail Making Test Parts A and B (TMT-A/B), and Controlled Oral Word Association (COWA). Individual deterioration was classified using the Reliable Change Index (RCI) with a 90% confidence interval, while patient-reported outcomes were assessed using MOS-CF and FACT-Br questionnaires.
  • Objective neurocognitive decline was common despite relatively stable average test performance. At least one neurocognitive test showed reliable deterioration in 50% of evaluable patients at six months and 40% at 12 months. Memory and processing speed were particularly affected: HVLT decline occurred in 21% and 20%, TMT-A decline in 29% and 20%, and TMT-B decline in 22% and 14%, respectively. Importantly, baseline performance was already more than one standard deviation below healthy normative values across the evaluated tests, indicating substantial cognitive impairment before chemoradiotherapy.
  • Patient-reported cognitive concerns did not consistently reflect objectively measured deterioration. Mean MOS-CF scores remained relatively stable, measuring 69.0 at baseline, 69.5 at six months, and 72.6 at 12 months. However, patients with reliable HVLT deterioration at one year reported substantially worsening cognitive concerns, with a mean MOS-CF change of −15.9 points versus +7.2 points among patients without HVLT deterioration (p=0.01). No corresponding significant associations were identified for the other neurocognitive tests, demonstrating that subjective cognitive reports cannot reliably substitute for standardized neuropsychological assessment.
  • Overall quality-of-life scores remained relatively stable, but meaningful deterioration occurred in a substantial minority. Using minimally important differences on the FACT-Br Brain Cancer subscale, 27% of patients deteriorated at six months and 25% at 12 months, despite stable or improved median group-level scores. Longitudinal modeling linked worse overall FACT-Br scores to disease progression (estimate −28.59; p=0.001), anticonvulsant use (−16.52; p=0.0029), and higher EORTC prognostic risk, while MGMT promoter methylation was associated with higher scores (+16.96; p=0.001). These exploratory associations do not establish causal relationships.
  • Tumor progression and unfavorable disease characteristics were associated with poorer neurocognitive performance. Progression was significantly associated with worse verbal learning (HVLT; p=0.014), processing speed (TMT-A; p=0.016), executive function (TMT-B; p=0.044), and verbal fluency (COWA; p=0.008). Greater numbers of high-risk factors and tumors crossing the midline were also associated with poorer performance on selected measures. However, baseline neurocognitive test scores were not independently associated with overall survival after adjustment for clinical and prognostic variables.
  • Missing follow-up data and historical molecular classification substantially limit interpretation. Completion rates exceeded 85% at baseline but fell to approximately 55–59% at six and 12 months, with only about 43% completing assessments at all three time points. IDH status was available for only 67/93 participants (72%), including 49 IDH-mutant and 18 IDH-wildtype tumors, while 1p/19q status and spatial brain dose-volume data were unavailable. The trial had no treatment control arm, so cognitive decline cannot be attributed specifically to radiotherapy, temozolomide, tumor progression, or their combined effects; furthermore, its legacy WHO grade II population does not map directly onto current molecularly defined glioma entities.

CLINICAL TAKEAWAY

Neurocognitive deterioration was frequent during the first year following RT–temozolomide for high-risk low-grade glioma, even though average cognitive and quality-of-life scores remained relatively stable. These findings support incorporating standardized, longitudinal neuropsychological assessment into glioma care rather than relying exclusively on brief screening instruments or patient-reported concerns. However, the single-arm design, substantial missing follow-up data, and historical molecular classification prevent conclusions about treatment-specific cognitive toxicity or the comparative safety of contemporary treatment strategies.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction